| NASDAQ: AGRX Forward - Looking Statements Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include “forward - looking statements.” We may, in some cases, use terms such as “predicts,” “believes,” “potential, ” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other wor ds that convey uncertainty of future events or outcomes to identify these forward - looking statements. Our forward - looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding our ongoing and planned manufacturing and commercialization of Twirla ® , the potential market acceptance and uptake of Twirla ® , including the increasing demand for Twirla, our partnership with Afaxys and its ability to promote growth, our future plans with respect to our debt financing from Perceptive Advisors, our operating expenses, financi al condition, growth and strategies, the length of time that we will be able to continue to fund our operating expenses and capi tal expenditures and our expected financing needs and sources of financing, our ability to maintain compliance with the listing requirements of the Nasdaq Capital Market, regulatory and legislative developments in the United States, and the expected benefits of our marketing and sales distribution strategies generally .. Any or all of the forward - looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward - looking statements are subject to risks and uncertainties including risks related to our ability to maintain regulatory approval of T wir la and the labeling under any approval we obtain, the ability of Corium to produce commercial supply in quantities and quality sufficien t t o satisfy market demand for Twirla, our ability to successfully enhance the commercialization and increase the uptake for Twirla, the s ize and growth of the markets for Twirla and our ability to serve those markets, regulatory and legislative developments in the Unite d S tates and foreign countries, our ability to obtain and maintain intellectual property protection for Twirla and our product candida tes , the effects of the ongoing COVID - 19 pandemic on our commercialization efforts, clinical trials, supply chain, operations and the operations of third parties we rely on for services such as manufacturing, marketing support and sales support, as well as on ou r potential customer base, our ability to maintain compliance with the listing requirements of the Nasdaq Capital Market, , and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10 - K and ou r Quarterly Reports on Form 10 - Q. These factors could cause actual results and developments to be materially different from those expressed in or implied by such statements. These forward - looking statements are made only as of the date of this presentation a nd the Company undertakes no obligation to publicly update such forward - looking statements to reflect subsequent events or circumstances. 2 |
